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Abstract
Xenon (Xe) is a noble gas that has been developed for use in people as an inhalational anesthestic and a diagnostic imaging
agent. Xe inhibits glutamatergic N-methyl-D-aspartate (NMDA) receptors involved in learning and memory and can affect
synaptic plasticity in the amygdala and hippocampus, two brain areas known to play a role in fear conditioning models of
post-traumatic stress disorder (PTSD). Because glutamate receptors also have been shown to play a role in fear memory
reconsolidation – a state in which recalled memories become susceptible to modification – we examined whether Xe
administered after fear memory reactivation could affect subsequent expression of fear-like behavior (freezing) in rats. Male
Sprague-Dawley rats were trained for contextual and cued fear conditioning and the effects of inhaled Xe (25%, 1 hr) on
fear memory reconsolidation were tested using conditioned freezing measured days or weeks after reactivation/Xe
administration. Xe administration immediately after fear memory reactivation significantly reduced conditioned freezing
when tested 48 h, 96 h or 18 d after reactivation/Xe administration. Xe did not affect freezing when treatment was delayed
until 2 h after reactivation or when administered in the absence of fear memory reactivation. These data suggest that Xe
substantially and persistently inhibits memory reconsolidation in a reactivation and time-dependent manner, that it could
be used as a new research tool to characterize reconsolidation and other memory processes, and that it could be developed
to treat people with PTSD and other disorders related to emotional memory.
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Introduction
Mitigation of persistent, intrusive, traumatic memories experi-
enced by people with post-traumatic stress disorder (PTSD)
remains a key therapeutic challenge [1]. Behavioral treatments
such as extinction training – administered alone or in combination
with cognitive-enhancing drugs (e.g. d-cycloserine) – attempt to
inhibit underlying traumatic memories by facilitating a new set of
learning contingencies, but often achieve limited success [2].
Another learning and memory phenomenon known as reconso-
lidation, a process by which reactivated (retrieved) memories
temporarily enter a labile state (the reconsolidation window), has
been studied to determine whether drug or behavioral interven-
tions can prevent a traumatic memory trace from being re-
incorporated back into the neural engram, inhibiting the memory
[3–6]. Several chemical agents have been found to inhibit fear
memory reconsolidation in animals [7] but unfortunately do not
translate well to humans, limiting their clinical use. They either are
toxic (e.g. protein synthesis inhibitors), induce unwanted side
effects, are slow acting such that brain drug concentrations peak
outside of the reconsolidation window, or are slowly eliminated
such that they interfere with later onset memory processes
including extinction [8]. A recent human study documented that
a single electroconvulsive therapy (ECT) treatment administered
to unipolar depressed subjects immediately after emotional
memory reactivation disrupted reconsolidation, confirming that
reconsolidation occurs in humans and that it can be inhibited by a
brief treatment [9]. While ECT is indicated for therapeutic use in
people with treatment-resistant major depression, it may not be a
viable treatment for other clinical populations. Thus, there is a
significant unmet need for a minimally invasive, safe and well-
tolerated treatment that can be used clinically to inhibit fear
memory reconsolidation in people with PTSD.
The noble gas xenon (Xe) inhibits glutamatergic N-methyl-D-
aspartate (NMDA) receptors [10] known to play a role in memory
reconsolidation [11]. Xe reduces NMDA-mediated synaptic
currents and neuronal plasticity in the basolateral amygdala and
CA1 region of the hippocampus [12,13]; these brain areas are
involved in Pavlovian fear conditioning, an animal model of PTSD
used to elucidate learning and memory processes, including
reconsolidation [14–16]. Xe already is used in humans at high
concentration (.50%) as an anesthetic and at subsedative
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applications, Xe has excellent safety/side effect profiles and is well
tolerated [17–19]. Further, NMDA receptor glycine antagonists
like Xe [10] do not appear to have significant abuse liability and
do not induce psychosis [20,21], consistent with clinical experience
[18,19]. Thus, Xe has a number of favorable properties that might
be beneficial for treating fear memory disorders. As fear memory
reconsolidation is an ‘‘evolutionarily conserved memory-update
mechanism’’ [5], we evaluated in rats whether administering a
subsedative concentration of Xe (maximum concentration 25%,
1 h) via inhalation following conditioned fear memory reactivation
could reduce subsequent expression of fear-like behavior. Here, we
report that Xe impaired reconsolidation of fear memory demon-
strated as a reduction in conditioned freezing, a behavioral
readout used to measure fear in animals.
Methods and Materials
Experimental subjects
Male Sprague-Dawley rats (Charles River; Raleigh, NC)
weighing 350–375 g were pair-housed in plastic Nalgene rat cages
and acclimated to the main animal vivarium for two weeks before
being randomly assigned to different treatment groups (below).
Rats were maintained on 12/12 h light dark cycles and food and
water were provided ad libitum. Experiments were performed
from 10 a.m. to 3 p.m. All animal handling was limited to the time
required to transport and place animals in the fear-conditioning
chambers and air/xenon exposure chambers (i.e., no pre-study
handling acclimation was used). The sample size was determined
in concordance with our previous work examining reconsolidation
mechanisms using the conditioned- freezing behavioral assay [22].
All animal procedures were approved by McLean Hospital’s
Institutional Animal Care and Use Committee (Office of
Laboratory Animal Welfare Assurance number A3685–01) in
accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (8
th Edition).
Fear-conditioning apparatus
Conditioning and testing were conducted in four identical
1969614 cm Plexiglas behavioral chambers contained in a
sound-attenuating cubicle (Med-Associates, Georgia VT). On the
training day, rats were placed in chambers and after 2 min
received two pairings of a 30 s, 5 kHz, 75 dB tone (conditioned
stimulus; CS) co-terminating with a 0.6 mA, 0.5 s footshock
(unconditioned stimulus; US) delivered through the floorbars of
the chamber. Shock reactivity (cage movement in response to
shock delivery) was measured after each training trial by an
accelerometer at the base of the cage. Accelerometer analog
output was amplified and digitized on a scale of 0–20 units by an
analog-to-digital card interfaced with a PC computer (Med-
Associates). Animals with shock reactivity levels ,3 units (aver-
aged across two training trials) were excluded as this can be used as
an indicator of the strength of conditioning (i.e. weak shock
reactivity) [23]; a total of 5 out of 99 animals were excluded based
on this criteria. The intertrial interval of CS-US pairings was 30 s.
After an additional 30 s in the chamber, animals were returned to
their home cages. Memory was reactivated (Reactivation) 24 h
after training by returning animals to testing chambers and after
2 min animals were exposed to the tone CS (5 kHz, 75 dB) for
60 s. Post-reactivation long-term memory (PR-LTM) was subse-
quently probed at 48 h (PR-LTM1), 96 h (PR-LTM2) or 18 d
(PR-LTM3) using Reactivation day procedures. Freezing behavior
was video-recorded on each day and scored by an experimenter
blind to treatment conditions. Percent freezing was calculated as
Figure 1. Xenon- (Xe) and oxygen (O2) gas concentration time course averaged across all exposures in this study. Percent Xe reflects
exposure chamber atmospheric Xe concentration along with oxygen (maintained at 20.9%) and balanced with nitrogen. The rate of Xe delivery was
approximately 2.5 liters per minute (supplied as 100% Xe from an external tank) and continuously mixed with chamber atmosphere by circulating
fans to reach a maximum preset concentration of 25%. Data included in the figure are from 14 total Xe exposures (Fig. 2B &C, n=3 runs; Fig. 2D & E,
n=3 runs; Fig. 2F & G, n=2 runs; Fig. 3 B & C, n=3 runs after Reactivation test and 3 runs after PR-LTM1). Data are shown as mean 6 s.e.m.
doi:10.1371/journal.pone.0106189.g001
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PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e106189Figure 2. Xenon exposure impairs reconsolidation and reduces conditioned freezing in a reactivation- and time-dependent
manner. (A) Schematic of the experimental design. Twenty-four h after fear conditioning, fear memories either were or were not reactivated and rats
were exposed either to Xe (25%) or Air for 1 h beginning either immediately or after a 2 h delay. An additional control group housed in the regular
main rat vivarium (Normal exposure) also was included in some studies to control for any potential effects of housing in the exposure chambers. Post-
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than breathing, during the first 2 min of re-exposure to the
chamber (Context) and during 60 s CS presentation (Tone).
Xenon exposure apparatus
A custom-built system (Air Products and Chemicals, Inc.;
Bethlehem, PA – APCI) was used to expose animals to 25% xenon
(Xe) gas (Praxair, Inc.; Danbury, CT). The apparatus consisted of
a3 0 624616 in. sealable Plexiglas chamber capable of housing
two modified Nalgene rat cages (perforated along all sides to
facilitate gas exchange) for exposure of up to four rats at a time (2
rats/cage). The delivery (rate and concentration) both of Xe and
supplemental oxygen (as needed to maintain 20.9% concentration;
Figure 1) was regulated by PC-interfaced mass-flow controllers
using custom-designed software (APCI). Xenon, oxygen, carbon
dioxide, pressure, temperature and humidity were all monitored
by sensors in the system and compensated as needed by the
internal control system and supporting equipment to maintain set
levels. An identical system was used for air exposures except that
only normal room air was supplied. Both the Xe and air-exposure
apparatuses were located in a dedicated animal quarantine bay
apart from the main vivarium but maintained under the same
environmental conditions.
Experimental procedures
After two-weeks acclimation in the main vivarium, pairs of rats
either were left in the rat housing room (Normal exposure group)
or re-located to the Xe (Xenon group) or Air (Air group) chambers
for further acclimation (1 week) to experimental-housing settings.
Rats then were trained for contextual and cued fear conditioning
using procedures adapted from Phillips and LeDoux [24].
Accordingly, this allowed us to evaluate the expression of
conditioned freezing in the presence of a conditioned stimulus
(CS, a tone) and the context (the conditioning/test chamber)
present during the training (CS pairing with shock, the uncondi-
tioned stimulus; US), and to examine effects of Xe administered
after memory reactivation on both components (freezing to
context and tone).
The timeline of procedures used for fear conditioning, testing
and Xe exposure is illustrated in Figures 2A & 3A. On Day 1,
rats were fear conditioned as described above. Twenty-four hours
later, immediately following reactivation testing, animals either
were placed in Xe or Air-exposure chambers, lids were sealed, and
animals were exposed to Xe (25%) or room air for 1 h. After 1 h,
Xe was completely scavenged by the Xe-exposure system and
chamber lids were opened to normal room air exposure for the
duration of the study.
A second set of animals was trained as described above but did
not receive a reactivation test 24 h later. Instead, at this time-
point, animals were exposed either to 25% Xe or Air for 1 h to
determine whether Xe must be paired with memory reactivation
for it to affect memory reconsolidation.
A third set of animals was trained as described above,
underwent reactivation 24 hours later, and were exposed either
to 25% Xe or Air (1 h, both types of exposure) beginning 2 h after
the reactivation test, to determine whether delayed Xe exposure
affected freezing at PR-LTM1 and PR-LTM2.
A fourth set of animals was trained as described above and
exposed either to 25% Xe or Air for 1 h twice; immediately after
reactivation and again after reactivation during PR-LTM1 testing,
to determine whether multiple Xe exposures enhance reconsolida-
tion blockade.
Statistics
Two-wayANOVAsfortreatmentgroup(between-subjects)6test
day (within-subjects) comparisons were performed. Comparisons
betweentreatmentgroupsfor thePR-LTM3testday(longtermtest
for spontaneous recovery), in a subset of animals, were performed
using one-way ANOVA. For measurements yielding significant
main effect, subsequent multiple pairwise comparisons were made
using Dunn’s test. All reported t tests are two-sided measures.
Results
Rats exposed to Xe (25%, 1 h) immediately after fear memory
reactivation exhibited a significant reduction of freezing when
tested 48 and 96 h after reactivation (PR-LTM1 and PR-LTM2,
respectively) compared to air-exposed controls (Fig. 2B & 2C).
Main effects: context alone (treatment group: F2,27=6.31,
P=0.006; test day: F2,54=10.41, P=0.0001; interaction:
F4,54=4.99, P=0.002); context + tone (treatment group:
F2,27=3.27, P=0.05; test day: F2,54=4.41, P=0.02; interaction:
F4,54=2.63, P=0.04). Xe-exposed rats exhibited a trend for
reduced freezing in the context + tone condition 48 h after
reactivation (P=0.06 compared to Air-exposure; P=0.02 com-
pared to main vivarium (Normal)- exposure); the reduction
attained statistical significance versus Air-exposed controls when
reassessed 96 h after reactivation (i.e. at PR-LTM2; Fig. 2C). In a
separate cohort treated identically to the first cohort up through
the PR-LTM1 test, the Xe effect on freezing to the context alone
finding was replicated while Xe significantly reduced freezing to
the context + tone at the first post-reactivation test (PR-LTM1;
Fig. 3B & 3C). When all observations of Xe effects on freezing at
PR-LTM1 were pooled from these two independent experiments
(Air-exposure, n=20; Xe-exposure, n=21) there was a highly
significant reduction in freezing both to context alone (t39=4.63,
P,0.0001) and context + tone (t39=2.16, P,0.01) compared to
air-exposed controls. Freezing at PR-LTM1 and PR-LTM2 did
not significantly differ.
In order to examine whether the amnestic effects of xenon were
long-lasting, a subset of animals from each treatment group was
further tested 18 days after the Reactivation test. On this test day
(PR-LTM3), freezing both to the context alone and to context +
tone was significantly reduced in Xe-exposed rats compared to
control groups, indicating a lack of spontaneous recovery of the
fear memory over time. Main effects: context alone (treatment
group: F2,16=3.76, P=0.04); context + tone (treatment group:
F2,16=10.93, P=0.001).
Figure 2D & E show that post-reactivation freezing to
context alone and context + tone (respectively) in rats that were
exposed to Xe but that did not receive a Reactivation test was
not significantly different from controls (no significant main
reactivation long-term memory (PR-LTM) was subsequently probed 48 h (PR-LTM1) and 96 h (PR-LTM2) later. A subset of rats (n=6–7/group) were
further tested for spontaneous recovery of freezing by testing 18 d after Reactivation (PR-LTM3). (B&C ) Percent freezing to context alone and
context + tone (respectively) in animals exposed to Xe (25%) or Air immediately after Reactivation. **P,0.005; *P,0.05 compared to Air exposure.
Normal exposure, n=8; Air exposure, n=11; Xe exposure, n=11. (D&E ) Percent freezing to context alone and context + tone in rats not receiving a
Reactivation test. Normal exposure, n=8; Air exposure, n=11; Xe exposure, n=11. (F&G ) Percent freezing to context alone and context + tone in
rats exposed either to Xe (25%) or Air beginning 2 h after Reactivation. Air exposure, n=7; Xe exposure, n=8. Data are shown as mean 6 s.e.m.
doi:10.1371/journal.pone.0106189.g002
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context alone and context + tone (respectively) in rats exposed to
Xe 2 h after Reactivation was not significantly different from
controls (no significant treatment effects). Together, these data
indicate that Xe was only effective at reducing long-term
expression of freezing when administered in conjunction with
memory reactivation and within the putative reconsolidation
window.
Figure 3B & C show that multiple Xe exposures after fear
memory reactivations do not further enhance the amnestic effects
of Xe on conditioned freezing. Main effects: Percent freezing to
context alone (treatment group: F1,17=14.9, P=0.001; test day:
F2,34=25.1, P,0.0001; interaction: F2,34=20.1, P,0.0001);
Figure 3. Multiple Xe exposures after fear memory reactivations do not enhance amnestic effects on conditioned freezing. (A)
Schematic of the experimental design for multiple Xe-exposure treatment. In addition to administering Xe (25%) or Air for 1 h after Reactivation,
animals were exposed a second time to Xe (25%) or Air for 1 h immediately after PR-LTM1 and freezing was again probed 48 h later, (PR-LTM2). (B&
C) Percent freezing to context alone and context + tone (respectively) in animals exposed to Xe (25%) or Air for 1 hr immediately after Reactivation
and PR-LTM1. (D&E ) Normalized freezing data to context and tone. Data are expressed as % differences from the first Reactivation test day in order
to compare the effects of multiple Xe exposures. A second Xe exposure did not alter freezing either to context alone or context + tone at PR-LTM2
compared to PR-LTM1. ***P,0.0005; **P,0.005; *P,0.05; Air–1 exposure, n=11; Air–2 exposures, n=9; Xe–1 exposure, n=11; Xe–2 exposures,
n=10. Data are shown as mean 6 s.e.m.
doi:10.1371/journal.pone.0106189.g003
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P=0.07; test day: F2,34=6.9, P=0.003; interaction: F2,34=4.2,
P=0.02). Figure 3D & E show normalized freezing data to
context alone and context + tone. Data are expressed as %
differences from the first Reactivation test day in order to compare
the effects of multiple Xe exposures. As shown, a second Xe
exposure did not alter freezing either to context alone or context +
tone at PR-LTM2 compared to PR-LTM1 (no significant
differences between PR-LTM1 and PR-LTM2).
Discussion
Here, we report for the first time, that inhaled administration of
a subsedative concentration of Xe gas substantially and persistently
inhibits a long-term fear memory, but only after memory
reactivation and when administered within the putative reconso-
lidation window [25]. NMDA receptor dynamics appear to play
key roles in both the destabilization and reconsolidation of
memory [11,26,27] and Xe’s rapid inhibition of these receptors
post-reactivation could mediate the effects we observed. Xe
directly reduces NMDA-mediated synaptic currents and affects
neuronal plasticity in the basolateral amygdala and CA1 region of
the hippocampus [12,13], brain areas known to play a role in fear
conditioning and which have been implicated in the pathophys-
iology of PTSD [28,29]. Xe also may indirectly reduce NMDA
receptor function by inhibiting the enzyme tissue plasminogen
activator (tPA) [30]. tPA increases NMDA receptor activity by
proteolytically cleaving the NR1 subunit amino terminal domain
[31]. Although tPA is best known as a clot-busting drug used in
acute stroke patients, tPA is released from dendrites during
synaptic activity [32], especially during high frequency stimulation
[33], tPA acts as a gliotransmitter [34], and tPA participates in
synaptic plasticity and learning and memory processes including
fear conditioning [35,36]. Xe also had been reported to affect
AMPA receptors [12] shown to play a role in memory
reconsolidation [37,38]. Collectively, Xe’s direct and indirect
inhibition of NMDA and AMPA receptor function may underlie
its ability to impair fear memory reconsolidation.
Other targets of Xe also could mediate the effects we observed.
For example, Xe has also been shown to have differential effects
on excitatory and inhibitory ligand-gated ion channels; Xe reduces
current through alpha4 beta2 (a4b2) nicotinic acetylcholine
receptor-gated channels and increases current through glycine
and GABAA receptor-gated channels [39]. Xe also targets other
proteins known to play a role in contextual fear memory including
alpha7 (a7) nicotinic acetylcholine receptors [40,41] and ATP-
dependent potassium (Kir6.2) channels [42,43], and targets
TREK-1 channels [44]. At this time, we cannot conclude which
targets of Xe mediate its inhibition of fear memory reconsolida-
tion, which is a limiting factor of this study. Future studies are
planned, however, using selective agonists and antagonists of these
and other receptors and proteins, to characterize the pharmacol-
ogy and mechanism of action of Xe’s effects on reconsolidation.
In our analysis of the pooled sample from all Xe-treated rats
(n=21) we found a within-subjects difference in Xe’s effects at PR-
LTM1 on freezing to context alone and context + tone whereby
freezing in the presence of the tone was less sensitive to Xe
(t20=3.72, P,0.005). These data suggest that Xe’s amnestic
effects may be stronger for context- versus cue-induced freezing.
This may reflect a stronger effect of Xe on the hippocampus than
the amygdala, which play different roles in context and cued-fear
conditioning [15,24]. This differential effect could be related to
Xe’s apparently greater inhibition of hippocampal versus amyg-
dala excitatory postsynaptic currents [12,13]. Interestingly, other
inhaled anesthetic agents, such as halothane, isoflurane, and
nitrous oxide, which can also affect learning and memory and
have amnestic effects, can alter hippocampal theta rhythms [45]
which have been shown to contribute to reconsolidation of
contextual fear memory by virtue of its synchronization with the
amygdala [46]. Hence, a preferential action of Xe on hippocampal
ensemble activities could account for the strong amnestic effect
upon re-exposure to the conditioning context (hippocampal
dependent), but which was reduced when the animal was then
presented with a discrete cue (amygdala dependent) within the
conditioning context. Clearly, a limitation of the current study is
that animals were not tested for cue-induced freezing in a different
context than that used for fear-conditioning, and that Xe was
tested in only one fear-conditioning paradigm. Our intention in
these initial studies was to elucidate the basic phenomenon using a
paradigm similar to that used in the seminal studies of Phillips and
LeDoux [24], which established a differential role for the
hippocampus and amygdala in context versus cued fear-condi-
tioning. Future studies investigating Xe’s effects on reconsolidation
for context- and cue-induced freezing, including freezing elicited
in a different context are planned, as well as studies involving
different fear conditioning paradigms.
As described in Tronson and Taylor [3], a number of control
protocols can be employed to demonstrate that a specific
treatment affects reconsolidation. The data presented in this
report include several of these important comparison groups.
First, we demonstrate that rats exposed to 25% Xe for 1 hour
in the absence of fear memory reactivation exhibited no
differences in freezing to context or tone versus air-exposed
controls (Fig. 2D & E). These data suggest that the effects of
Xe on reconsolidation and impairment of long-term fear
memory are not due to non-specific effects of Xe gas inhalation,
but that Xe’s effects likely are having a direct effect on brain
mechanisms engaged only after the fear memory is recalled.
Second, when Xe administration was delayed until 2 hours after
fear memory reactivation, a time point expected to be outside of
the reconsolidation window for NMDA antagonists [25], Xe
was ineffective at reducing freezing (Fig. 2F & G). Together,
these results suggest that 25% Xe inhibits fear memory
reconsolidation only after fear memory reactivation and only
when administered within the reconsolidation window. These
findings along with our data showing a lack of spontaneous
recovery – a traditional test used to examine the enduring
amnestic effect of a treatment [47] – document that Xe satisfies
several requirements of a demonstrable reconsolidation-blocking
agent.
Lastly, we examined whether a second 25% Xe exposure for 1
hour immediately after the PR-LTM1 test (which is, itself, another
memory reactivation), could further impair reconsolidation. The
second Xe exposure did not further affect freezing to context alone
or context + tone (Fig. 3B & 3C) when compared with Xe
administered only after first reactivation (Fig. 3D & 3E). Possible
interpretations of this finding include that the Xe-sensitive
component of reconsolidation may have a threshold for its
amnestic capacity after blockade and/or that residual fear
maintenance may occur by Xe-insensitive mechanisms. A recent
study reported that a transition state may develop after multiple
unreinforced CS exposures reflecting a dynamic shift from
reconsolidation to extinction processes, during which NMDA
receptor antagonists lose their ability to affect reconsolidation or
extinction [48]. As both processes are NMDA-receptor dependent
[11], it is possible that a first treatment with Xe and the ensuing
amnestic effect may shift the reconsolidation-extinction boundaries
to limit the effectiveness of a second treatment. Xe’s rapid on-off
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temporally precise tool to help characterize such transition states
and other dynamic memory processes. Given that the timing of
interventions aimed at blocking reconsolidation or enhancing
extinction may significantly affect treatment outcomes [11,48],
Xe’s rapid kinetics also may enable temporally optimized
treatment regimens.
In summary, we report in an animal model of PTSD that 25%
Xe administered within the reconsolidation window after fear
memory reactivation substantially reduced subsequent fear
memory expression. This anxiolytic-like effect in rats has
translational application to current clinical research aimed at
modulating memory processes as a therapy for fear and anxiety
disorders [50–53]. People with PTSD experience intrusive,
persistent traumatic memories [54], impaired fear memory
extinction [55], and may be locked in reconsolidation mode
[56]. Given that fear memory reconsolidation is ‘‘evolutionarily
conserved’’ [5] and that subsedative Xe inhalation is associated
with well-established excellent safety and side-effect profiles in
humans [18,19] Xe appears to have potential for rapid
development as a pharmacotherapy to inhibit traumatic memory
reconsolidation in PTSD patients, and possibly treat other
conditions involving reconsolidation, including addiction disor-
ders [56,57].
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